Sero‐prevalence of SARS‐CoV‐2 in certain cities of Kazakhstan
Abstract Background and Aims Seroprevalence studies are needed to determine the cumulative prevalence of SARS‐CoV‐2 infection and to develop pandemic mitigation strategies. Despite the constant monitoring and surveillance, the true level of infection in the population of Kazakhstan remains unknown....
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-03-01
|
| Series: | Health Science Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/hsr2.562 |
| _version_ | 1797224949904048128 |
|---|---|
| author | Manar Smagul Aizhan Esmagambetova Gauhar Nusupbaeva Ulyana Kirpicheva Lena Kasabekova Gauhar Nukenova Timur Saliev Ildar Fakhradiyev Shynar Tanabayeva Baurzhan Zhussupov |
| author_facet | Manar Smagul Aizhan Esmagambetova Gauhar Nusupbaeva Ulyana Kirpicheva Lena Kasabekova Gauhar Nukenova Timur Saliev Ildar Fakhradiyev Shynar Tanabayeva Baurzhan Zhussupov |
| author_sort | Manar Smagul |
| collection | DOAJ |
| description | Abstract Background and Aims Seroprevalence studies are needed to determine the cumulative prevalence of SARS‐CoV‐2 infection and to develop pandemic mitigation strategies. Despite the constant monitoring and surveillance, the true level of infection in the population of Kazakhstan remains unknown. The aim of this study was to determine the sero‐prevalence of SARS‐CoV‐2 in the main cities of Kazakhstan. Methods The research was conducted as a cluster‐randomized cross‐sectional national household study in three cities of Kazakhstan. The study covered the period: from October 24, 2020, to January 11, 2021. A total of 5739 people took part in the study. All participants agreed to be tested for antibodies to IgM/IgG. Demographic characteristics were analyzed. The presence of symptoms of respiratory diseases and the results of polymerase chain reaction (PCR) testing were determined. The antibodies to the SARS‐CoV‐2 virus were detected using the method of enzyme‐linked immunosorbent assay (ELISA). Results There was significant geographic variability with a higher prevalence of IgG/IgM antibodies to SARS‐CoV‐2 in Almaty 57.0%, in Oskemen 60.7% than in Kostanay 39.4%. There were no significant differences in prevalence between men and women (p ≥ 0.05). In Almaty, only 19% of participants with antibodies reported the presence of respiratory symptoms during a pandemic. At the same time, the percentage of patients with antibodies who had respiratory symptoms was 36% in Oskemen and 27% in Kostanay. Conclusion The findings indicate that despite reasonable level of seroprevalence, the country has not yet reached the baseline minimum of herd immunity scores. The prevalence estimates for asymptomatic or subclinical forms of the disease ranged from 64% to 81%. Thus, given that almost half of the population of Kazakhstan remains vulnerable, the importance of preventive strategies such as social distancing, the use of medical masks, and vaccination to protect the population from the transmission of SARS‐CoV‐2 is highly critical. |
| first_indexed | 2024-03-12T13:33:23Z |
| format | Article |
| id | doaj.art-7e4cf4f1c98346708881612c16e529b3 |
| institution | Directory Open Access Journal |
| issn | 2398-8835 |
| language | English |
| last_indexed | 2024-04-24T14:01:15Z |
| publishDate | 2022-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Health Science Reports |
| spelling | doaj.art-7e4cf4f1c98346708881612c16e529b32024-04-03T12:41:03ZengWileyHealth Science Reports2398-88352022-03-0152n/an/a10.1002/hsr2.562Sero‐prevalence of SARS‐CoV‐2 in certain cities of KazakhstanManar Smagul0Aizhan Esmagambetova1Gauhar Nusupbaeva2Ulyana Kirpicheva3Lena Kasabekova4Gauhar Nukenova5Timur Saliev6Ildar Fakhradiyev7Shynar Tanabayeva8Baurzhan Zhussupov9“Scientific and Practical Center for Sanitary and Epidemiological Expertise and Monitoring” Branch of the National Center for Public Health of the Ministry of Healthcare of the Republic of Kazakhstan Nur‐Sultan Republic of KazakhstanCommittee of Sanitary and Epidemiological Control of the Ministry of Healthcare of the Republic of Kazakhstan Nur‐Sultan Republic of Kazakhstan“Scientific and Practical Center for Sanitary and Epidemiological Expertise and Monitoring” Branch of the National Center for Public Health of the Ministry of Healthcare of the Republic of Kazakhstan Nur‐Sultan Republic of Kazakhstan“Scientific and Practical Center for Sanitary and Epidemiological Expertise and Monitoring” Branch of the National Center for Public Health of the Ministry of Healthcare of the Republic of Kazakhstan Nur‐Sultan Republic of Kazakhstan“Scientific and Practical Center for Sanitary and Epidemiological Expertise and Monitoring” Branch of the National Center for Public Health of the Ministry of Healthcare of the Republic of Kazakhstan Nur‐Sultan Republic of Kazakhstan“Scientific and Practical Center for Sanitary and Epidemiological Expertise and Monitoring” Branch of the National Center for Public Health of the Ministry of Healthcare of the Republic of Kazakhstan Nur‐Sultan Republic of KazakhstanS. D. Asfendiyarov Kazakh National Medical University Almaty Republic of KazakhstanS. D. Asfendiyarov Kazakh National Medical University Almaty Republic of KazakhstanS. D. Asfendiyarov Kazakh National Medical University Almaty Republic of KazakhstanS. D. Asfendiyarov Kazakh National Medical University Almaty Republic of KazakhstanAbstract Background and Aims Seroprevalence studies are needed to determine the cumulative prevalence of SARS‐CoV‐2 infection and to develop pandemic mitigation strategies. Despite the constant monitoring and surveillance, the true level of infection in the population of Kazakhstan remains unknown. The aim of this study was to determine the sero‐prevalence of SARS‐CoV‐2 in the main cities of Kazakhstan. Methods The research was conducted as a cluster‐randomized cross‐sectional national household study in three cities of Kazakhstan. The study covered the period: from October 24, 2020, to January 11, 2021. A total of 5739 people took part in the study. All participants agreed to be tested for antibodies to IgM/IgG. Demographic characteristics were analyzed. The presence of symptoms of respiratory diseases and the results of polymerase chain reaction (PCR) testing were determined. The antibodies to the SARS‐CoV‐2 virus were detected using the method of enzyme‐linked immunosorbent assay (ELISA). Results There was significant geographic variability with a higher prevalence of IgG/IgM antibodies to SARS‐CoV‐2 in Almaty 57.0%, in Oskemen 60.7% than in Kostanay 39.4%. There were no significant differences in prevalence between men and women (p ≥ 0.05). In Almaty, only 19% of participants with antibodies reported the presence of respiratory symptoms during a pandemic. At the same time, the percentage of patients with antibodies who had respiratory symptoms was 36% in Oskemen and 27% in Kostanay. Conclusion The findings indicate that despite reasonable level of seroprevalence, the country has not yet reached the baseline minimum of herd immunity scores. The prevalence estimates for asymptomatic or subclinical forms of the disease ranged from 64% to 81%. Thus, given that almost half of the population of Kazakhstan remains vulnerable, the importance of preventive strategies such as social distancing, the use of medical masks, and vaccination to protect the population from the transmission of SARS‐CoV‐2 is highly critical.https://doi.org/10.1002/hsr2.562antibodiesasymptomaticCOVID‐19SARS‐CoV‐2seroprevalence |
| spellingShingle | Manar Smagul Aizhan Esmagambetova Gauhar Nusupbaeva Ulyana Kirpicheva Lena Kasabekova Gauhar Nukenova Timur Saliev Ildar Fakhradiyev Shynar Tanabayeva Baurzhan Zhussupov Sero‐prevalence of SARS‐CoV‐2 in certain cities of Kazakhstan Health Science Reports antibodies asymptomatic COVID‐19 SARS‐CoV‐2 seroprevalence |
| title | Sero‐prevalence of SARS‐CoV‐2 in certain cities of Kazakhstan |
| title_full | Sero‐prevalence of SARS‐CoV‐2 in certain cities of Kazakhstan |
| title_fullStr | Sero‐prevalence of SARS‐CoV‐2 in certain cities of Kazakhstan |
| title_full_unstemmed | Sero‐prevalence of SARS‐CoV‐2 in certain cities of Kazakhstan |
| title_short | Sero‐prevalence of SARS‐CoV‐2 in certain cities of Kazakhstan |
| title_sort | sero prevalence of sars cov 2 in certain cities of kazakhstan |
| topic | antibodies asymptomatic COVID‐19 SARS‐CoV‐2 seroprevalence |
| url | https://doi.org/10.1002/hsr2.562 |
| work_keys_str_mv | AT manarsmagul seroprevalenceofsarscov2incertaincitiesofkazakhstan AT aizhanesmagambetova seroprevalenceofsarscov2incertaincitiesofkazakhstan AT gauharnusupbaeva seroprevalenceofsarscov2incertaincitiesofkazakhstan AT ulyanakirpicheva seroprevalenceofsarscov2incertaincitiesofkazakhstan AT lenakasabekova seroprevalenceofsarscov2incertaincitiesofkazakhstan AT gauharnukenova seroprevalenceofsarscov2incertaincitiesofkazakhstan AT timursaliev seroprevalenceofsarscov2incertaincitiesofkazakhstan AT ildarfakhradiyev seroprevalenceofsarscov2incertaincitiesofkazakhstan AT shynartanabayeva seroprevalenceofsarscov2incertaincitiesofkazakhstan AT baurzhanzhussupov seroprevalenceofsarscov2incertaincitiesofkazakhstan |